mission
We protect people’s lives and health, producing the world’s best technologies which are available for everyone to everyone
AboutNews
Vaccines
18.1
billion rubles
the company's turnover in 2023
42
%
the average
annual rate of growth in 2017-2023
200
million
tablets have been produced since 2014 — enough to lay a road from Kirov to the “Vostok” Antartic station
15
million
children in Russia have already been immunized with vaccines produced by “Nanolek”
Plant
At the innovative Nanolek Plant in the Kirov region medicines are produced according to international GMP* and ISO 9001 standards**
Drugs for the treatment of cancer
Bavencio
Avelumab — Human Immunoglobulin Gl, Monoclonal antibody
Brukinza
Zanubrutinib is a selective low—molecular-weight inhibitor of Bruton tyrosine kinase, an oncohematological drug
Darzalex
Daratumumab is a monoclonal antibody that acts on the CD38 surface protein
Lomustine
Lomustin is an antitumor drug of alkylating action
Neupomax
Filgrastim — recombinant human granulocyte colony stimulating factor
Stibevara
Bevacizumab is a recombinant hyperchymeric monoclonal IgG1 antibody
Tretinoin
Tretinoin
Drugs for the treatment of orphan diseases
Hunterase
Iduronate-2-sulfatase is a drug for enzyme replacement therapy for Hunter syndrome
R&D
Nanolek’s own R&D centre by the same name was opened in 2021 in the science city of Pushchino with the goal of developing new medicines there from scratch.
The path of a drug from a molecule to market entry takes up to 6 years. Early development of development of a single molecule takes 1-2 years. Furthermore, on average only 10 out of 100 hypotheses of molecules make it to market.
The Nanolek R&D Center operates on the basis of the Pushchinsky Institute of Biological Instrumentation of the Russian Academy of Sciences. These scientists focus on new methods and technologies in physico-chemical biology, medicine, and pharmacology.